EMA Authorised: Ontruzant (trastuzumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

EMA authorised Ontruzant (trastuzumab) from Samsung Bioepis NL B.V., a biosimilar to trastuzumab for breast and gastric cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• ONTRUZANT (TRASTUZUMAB)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms;Breast Neoplasms. MAH: Samsung Bioepis NL B.V.. Decision date: 22/01/2026